HROW
Harrow Health, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$38.54
+0.73%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 275.6M | 272.3M | 199.6M | 130.2M | 88.6M |
| Cost of Revenue | 73.6M | 67.9M | 49.2M | 39.6M | 25.4M |
| Gross Profit | 202.0M | 204.4M | 150.4M | 90.6M | 63.2M |
| Operating Expenses | |||||
| R&D Expense | 20.6M | 12.8M | 12.2M | 6.7M | 3.0M |
| SG&A Expense | 139.8M | 152.9M | — | — | — |
| General & Admin Expense | 53.3M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 35.9M | — | 129.3M | 83.5M | 58.2M |
| Total Operating Expenses | 196.3M | 165.8M | 141.5M | 90.1M | 61.3M |
| Cost and Expenses | 269.9M | 233.7M | 190.8M | 129.8M | 86.7M |
| Operating Income (EBIT) | 5.7M | 38.6M | 8.8M | 431.0K | 1.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 23.0M | 24.2M | 22.8M | 21.3M | 7.2M |
| Net Interest Income | (23.0M) | (24.2M) | (22.8M) | (21.3M) | (7.2M) |
| Other Non-Op Income/Expense | (39.1M) | (40.3M) | (26.1M) | (24.1M) | (15.9M) |
| Non-Operating Income (excl Interest) | 16.1M | 16.2M | (253.0K) | (380.0K) | 8.7M |
| EBT (Pre-Tax Income) | (33.4M) | (1.7M) | (17.3M) | (23.7M) | (14.0M) |
| Income Tax Expense | 3.8M | 3.4M | 161.0K | 701.0K | 75.0K |
| Bottom Line | |||||
| Net Income | (37.2M) | (5.1M) | (17.5M) | (24.4M) | (14.1M) |
| Earnings from Cont. Ops | (37.2M) | (5.1M) | (17.5M) | (24.4M) | (14.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (37.2M) | (5.1M) | (17.5M) | (24.4M) | (14.1M) |
| Per Share | |||||
| Basic EPS | ($0.99) | ($0.14) | ($0.49) | ($0.75) | ($0.51) |
| Diluted EPS | ($0.99) | ($0.14) | ($0.49) | ($0.75) | ($0.51) |
| Revenue Per Share | $7.38 | $7.41 | $5.60 | $3.99 | $3.23 |
| Shares | |||||
| Basic Shares Outstanding | 37.4M | 36.8M | 35.7M | 32.6M | 27.5M |
| Diluted Shares Outstanding | 37.4M | 36.8M | 35.7M | 32.6M | 27.5M |
| Profitability Metrics | |||||
| EBITDA | 4.5M | 41.4M | 22.1M | 11.9M | (3.9M) |
| D&A | 14.9M | 18.9M | 13.1M | 11.1M | 2.8M |
| EBIT | (10.4M) | 22.5M | 9.1M | 811.0K | (6.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026